Published in Pharma Law Weekly, August 31st, 2004
Cymbalta, a balanced reuptake inhibitor of serotonin and norepinephrine, has been studied in more than 6,000 adults with major depression worldwide. Its approval gives healthcare professionals and patients a long-awaited new option for treating the broad range of emotional and physical symptoms of depression. Today, only 25-35% of patients treated for depression in clinical studies experience relief from all of their disease symptoms.
"Depression is a whole-body...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly